Evidence for the involvement of descending pain-inhibitory mechanisms in the antinociceptive effect of hecogenin acetate.

dc.creatorGama, Kelly Barbosa
dc.creatorQuintans, Jullyana de Souza Siqueira
dc.creatorAntoniolli, Angelo Roberto
dc.creatorQuintans Junior, Lucindo José
dc.creatorSantana, Wagno Alcântara
dc.creatorBranco, Alexsandro
dc.creatorSoares, Milena Botelho Pereira
dc.creatorVillarreal, Cristiane Flora
dc.date2014-10-08T19:34:21Z
dc.date2014-10-08T19:34:21Z
dc.date2013
dc.date.accessioned2023-09-26T23:09:32Z
dc.date.available2023-09-26T23:09:32Z
dc.identifierGAMA, K. B. et al. Evidence for the involvement of descending pain-inhibitory mechanisms in the antinociceptive effect of hecogenin acetate. Journal of Natural Products, v. 76, n. 4, p. 559-563, 2013.
dc.identifier1520-6025
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/8554
dc.identifier10.1021/np3007342
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8887498
dc.descriptionHecogenin is a sapogenin present in the leaves of species from the Agave genus, with a wide spectrum of reported pharmacological activities. The present study was undertaken to evaluate whether hecogenin acetate (1) has antinociceptive properties and to determine its mechanism of action. The nociceptive threshold was evaluated using the tail flick test in mice. Mice motor performance was evaluated in a Rotarod test. By using Fos expression as a marker of neural activation, the involvement of the periaqueductal gray in 1-induced antinociception was evaluated. Intraperitoneal administration of 1 (5−40 mg/kg) produced a dose-dependent increase in the tail flick latency time compared to vehicle-treated group (p < 0.01). Mice treated with 1 (40 mg/kg) did not show motor performance alterations. The antinociception of 1 (40 mg/kg) was prevented by naloxone (nonselective opioid receptor antagonist; 5 mg/kg), CTOP (μ-opioid receptor antagonist; 1 mg/kg), nor-BNI (κ- opioid receptor antagonist; 0.5 mg/kg), naltrindole (δ-opioid receptor antagonist; 3 mg/kg), or glibenclamide (ATP-sensitive K+ channel blocker; 2 mg/kg). Systemic administration of 1 (5−40 mg/kg) increased the number of Fos positive cells in the periaqueductal gray. The present study has demonstrated for the first time that 1 produces consistent antinociception mediated by opioid receptors and endogenous analgesic mechanisms
dc.formatapplication/pdf
dc.languageeng
dc.publisherACS Publications
dc.rightsopen access
dc.subjectAgave/química
dc.subjectAnalgésicos/farmacologia
dc.subjectDor/quimioterapia
dc.subjectCompostos de Espiro/farmacologia
dc.subjectEsteroides/farmacologia
dc.subjectAnimais
dc.subjectGlibureto/farmacologia
dc.subjectCanais KATP/antagonistas & inibidores
dc.subjectMasculino
dc.subjectCamundongos
dc.subjectEstrutura Molecular
dc.subjectNaltrexona/farmacologia
dc.subjectSubstância Cinzenta Periaquedutal/efeitos de drogas
dc.subjectFolhas de Planta/química
dc.subjectReceptores Opioides kappa/antagonistas & inibidores
dc.titleEvidence for the involvement of descending pain-inhibitory mechanisms in the antinociceptive effect of hecogenin acetate.
dc.typeArticle


Este ítem pertenece a la siguiente institución